Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $1.66
Key levels
Resistance$1.81
Resistance$1.66
Support$1.36
Latest news & SEC filings
SEC FilingLipocine Inc. filed a report on a major company event (Form 8-K)
EarningsLipocine Posts Q3 2026 Financials
EarningsLipocine posts smaller quarterly loss than expected, revenue tops forecast
All LPCN news →Lipocine is a biopharmaceutical company that develops oral drug delivery technologies for molecules that are otherwise hard to administer by mouth. Its main product is TLANDO, an oral testosterone replacement therapy for adult men with low or absent testosterone, licensed to partners for the U.S., Canada, South Korea, the Gulf Cooperation Council countries, and Brazil. Its pipeline includes oral candidates for postpartum depression, major depressive disorder, essential tremor, epilepsy, and obesity-related body composition, along with liver disease and preterm birth programs. The company operates in the United States.
Based on the company's 10-K filed Mar 10, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LPCN.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$6.92
27
Moat Score
NONE
0/9
Piotroski Score
-16.1
Altman Z-Score
Insider Signal
BUYING
7 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Higuchi John W. | director | Buy | 15,970 | $36K | Sep 30, 2026 |
| Higuchi John W. | director | Buy | 9,037 | $19K | Sep 29, 2026 |
| Higuchi John W. | director | Buy | 12,561 | $27K | Sep 28, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-82.3%
3yr Revenue CAGR
-50.3%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for LPCN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:19:07 | $1.61 | 1,000 | $$2K | BUY |
| 20:50:07 | $1.58 | 1,100 | $$2K | BUY |
| 20:42:20 | $1.57 | 1,500 | $$2K | BUY |
| 20:42:20 | $1.57 | 5,000 | $$8K | BUY |
| 20:28:55 | $1.57 | 1,600 | $$3K | SELL |
5 dark pool trades shown · $$16K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Lipocine Inc. (LPCN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings intelligence, and a complete investment thesis with entry and exit recommendations.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Lipocine Inc. (LPCN) is at $1.57, up 2.61% (+$0.04) at the Nov 6, 2026 close.
Latest LPCN news — Nov 5, 2026: Lipocine Inc. filed a report on a major company event (Form 8-K) · Nov 5, 2026: Lipocine Posts Q3 2026 Financials
Lipocine shares fell sharply today, closing at $2.20, down 25.42% from the open of $2.95, despite positive news that Health Canada approved TLANDO for testosterone replacement therapy in adult males. The stock traded in a wide range between $2.07 and $3.15 on heavy volume of over 28 million shares.
Analyst ratings for LPCN: 1 Buy, 1 Hold, 0 Sell — consensus Buy.
LPCN last reported on Aug 4, 2026: EPS -$0.32 vs -$0.40 expected — a beat of 20.0%.
Support: $1.36. Resistance: $1.66, $1.81, $2.06.
Insider activity: BUYING, 7 buys and 0 sells in the last 90 days.
Nov 5, 2026: Lipocine Inc. filed a report on a major company event (Form 8-K) · Nov 5, 2026: Lipocine Posts Q3 2026 Financials · Nov 5, 2026: Lipocine posts smaller quarterly loss than expected, revenue tops forecast